Show simple item record

dc.contributor.authorSigmond, J.en_US
dc.contributor.authorKroep, J.R.en_US
dc.contributor.authorLoves, Wen_US
dc.contributor.authorCodacci-Pisanelli, G.en_US
dc.contributor.authorPeters, G.J.en_US
dc.date.accessioned2011-11-14T14:27:57Z
dc.date.issued2004en_US
dc.identifier.citationCancer Letters, 213(2), 173-9en_US
dc.identifier.issn0304-3835
dc.identifier.urihttp://hdl.handle.net/1871/25980
dc.description.abstract0.0001), enzyme activity (Pearson: r = 0.972; P = 0.003) and gemcitabine sensitivity (Pearson: r = 0.695; P = 0.048). The LC-PCR was also applied to needle biopsy specimens. In bladder tumors a similar correlation was found, while esophageal tumors with a high dCK expression responded to gemcitabine treatment. The LC is a rapid and reliable method for quantitation of dCK mRNA levels in tumors to predict clinical gemcitabine sensitivity.en_US
dc.relation.uri10.1016/j.canlet.2004.04.016
dc.titleQuantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.en_US
dc.typeArticle / Letter to editoren_US
dc.creator.metisIdVU1059448
dc.creator.metisIdVU1021616
dc.creator.metisIdVU1066765
dc.creator.metisIdVU1027315
dc.creator.metisIdVU1022108
dc.identifier.metisId170361
dc.provenance.metis2005-01-21 16:05
dc.source.volume213
dc.source.journalTitleCancer Lettersen_US
dc.source.startpage173
dc.source.endpage9
dc.source.issue2
dc.creator.facultyVU medisch centrumnl_NL
dc.creator.facultyVU medisch centrumnl_NL
dc.creator.facultyVU medisch centrumnl_NL
dc.coverage.researchinstituteVUmc CCA 04nl_NL
dc.date.updated2014-02-07T10:20:17Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record